Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ADVANZ PHARMA Corp. Limited

https://www.advanzpharma.com/

Latest From ADVANZ PHARMA Corp. Limited

Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances

More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.

Scrip Asks Advanced Therapies

Finance Watch: Scion Life Sciences Launches With $310m Inaugural VC Fund

Private Company Edition: Scion’s first fund exceeded its initial $250m fundraising goal. Also, The Column Group’s incubator raised a $400m-plus fund and Seroba’s fourth fund reaches $134m, while Neurona raised a $120m financing and Cour closed a $105m series A round.

Financing Innovation

Rare Disease Drug Govorestat & Odevixibat Resubmission Among New EU Filings

The latest marketing applications under review by the European Medicines Agency include govorestat for classic galactosemia, a condition for which there are no treatments, and odevixibat for Alagille syndrome.

Europe Drug Review

Finance Watch: Stark Contrast As Big FOPOs Reach Market, Other Firms Cut Costs

Public Company Edition: Arvinas grossed $350m in a private placement, while Xenon brought in $345m and Pharvaris raised $300m in follow-on public offerings. Fundraising remains challenging, however, so IGM Biosciences, Hansa Biopharma and other companies cut costs to save money.

Financing Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • ADVANZ PHARMA
    • ADVANZ PHARMA Corp. Limited
    • Amdipharm Mercury Limited
    • Concordia Healthcare Corp.
    • Concordia International Corp.
    • Concordia Laboratories, Inc.
    • Concordia Pharmaceuticals, Inc.
    • Covis Pharma S.à.r.l, Covis Injectables, S.à.r.l
    • Correvio Pharma Corp
UsernamePublicRestriction

Register